Zobrazeno 1 - 10
of 53
pro vyhledávání: '"E P, Mauser Bunschoten"'
Publikováno v:
Hamostaseologie. 33(4)
Patients with haemophilia (PWH) are relatively protected from cardiovascular death. Recent insights have shown that this is not due to less formation of atherosclerosis than in non-haemophilic men, therefore protection from the final occlusive thromb
Autor:
Y.V. Sanders, Pieter Willem Kamphuisen, B.A. Laros-Van Gorkum, Karin Fijnvandraat, J. Eikenboom, Marjon H. Cnossen, M. Degenaar-Dujardin, E. P. Mauser Bunschoten, Karina Meijer, E. M. De Wee, J. G. van der Bom
Publikováno v:
Haemophilia. 18:11-51
Background and Aims: Von Willebrand disease (VWD) is caused by reduced levels of or dysfunctional von Willebrand factor (VWF) and is characterized by a bleeding tendency. It is well known that individuals with high VWF levels have a higher risk for a
Autor:
Diederick E. Grobbee, Roger E. G. Schutgens, Douwe H. Biesma, E. P. Mauser Bunschoten, G. Roosendaal, Krista Fischer, I. E. M. Den Uijl
Publikováno v:
Haemophilia. 17:849-853
The classification of haemophilia originates from 1950s and has been adopted unchallengedly by the ISTH in 2001. The aim of this study was: does the current classification compare onset of bleeding and age at first treatment, as well as annual joint
Publikováno v:
Haemophilia, 14, 147-152. Wiley
New imaging techniques are valuable for the care of patients with haemophilia. On angiography it is shown that some bleedings in severely damaged joints or after implantation of prostheses are arterial. Effect of clotting factor is often poor. Select
Autor:
Yvonne V, Sanders, Karin, Fijnvandraat, Johan, Boender, Evelien P, Mauser-Bunschoten, Johanna G, van der Bom, Joke, de Meris, Frans J, Smiers, Bernd, Granzen, Paul, Brons, Rienk Y J, Tamminga, Marjon H, Cnossen, Frank W G, Leebeek, E P, Mauser-Bunschoten
Publikováno v:
American journal of hematology. 90(12)
The bleeding phenotype of children with von Willebrand disease (VWD) needs to be characterized in detail to facilitate diagnosis during childhood and aid in the planning and assessment of treatment strategies. The objective was to evaluate the occurr
Autor:
Ian R. Peake, B. T. Colvin, F. E. Preston, E. P. Mauser Bunschoten, Charles R. M. Hay, F. G. H. Hill, R. Bagnall, N. Wasseem, Karin Fijnvandraat, G. White, E. Santagostino, C. A. Ludlam, Erik Berntorp, Carol K. Kasper
Publikováno v:
Thrombosis and Haemostasis. 79:762-766
SummaryTwenty six patients with mild or moderate haemophilia A and inhibitors are described. The inhibitor was detected at a median age of 33 years, after a median of 5.5 bleeding episodes. This usually following intensive replacement therapy. The me
Publikováno v:
Blood. 86:983-988
In patients with hemophilia A and inhibitory alloantibodies against factor VIII, various dosage schedules are used to obtain immune tolerance. In this study, we have evaluated the results of 13 years of low-dose immune tolerance induction and factors
Autor:
D M W, Balak, S C, Gouw, I, Plug, E P, Mauser-Bunschoten, A H J T, Vriends, J E M, Van Diemen-Homan, F R, Rosendaal, J G, van der Bom
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia. 18(4)
Carriers of haemophilia face difficult choices regarding prenatal diagnosis, but little is known about the determinants that influence their decisions. The aim of this study was to assess the incidence of prenatal diagnosis and potential determinants
Autor:
E P Mauser-Bunschoten, F R Rosendaal, H K Nieuwenhuis, G Roosendaal, E Briëf, H M van den Berg
Publikováno v:
Thrombosis and Haemostasis. 71:703-706
Department of Hematology, University Hospital, Leiden, The NetherlandsSummaryAfter the mtroduction of a new pasteunsed factor VIII concentrate(Factor VIIICPS-P) m The Netherlands rn June 1990, an mcrease m theoccurrence of inhibitois m hemophihaA pat